Docetaxel's main therapeutic mode of action is the suppression of microtubule dynamic assembly and disassembly, rather than microtubule bundling, leading to apoptosis, and the blocking of Bcl-2 expression.[26, 27] Docetaxel plays a major role in the management of advanced HRPC, but when the tumor acquires resistance to docetaxel, an active second-line chemotherapy is needed. Here, BCL2 is linked to neoplasm.